IMPRINT will rapidly expand the breadth of UTA’s clinical and translational research programs through innovations in diagnostics and drug development, driving transformative innovation in biomedical sciences and improving healthcare outcomes for all.
Key Areas of Focus
- Biomanufacturing
- Precision Medicine
- Entrepreneurship and Commercialization
Collaborative Research
UTA IMPRINT Antibody Discovery Program
UTA, through its IMPRINT initiative, has launched a transformative antibody discovery program powered by the Beacon Discovery Platform. This program establishes UTA as a regional hub for antibody innovation, integrating cutting-edge biomanufacturing, genomics, and translational research.
Led by Dr. Jon Weidanz, a recognized innovator in cancer immunotherapy, this program is designed to accelerate both academic and commercial breakthroughs in antibody-based therapeutics. By leveraging UTA’s comprehensive translational pipeline- from discovery (IMPRINT) to sequencing (NTGC) to scale-up biomanufacturing (NCTM2)- partners gain an unparalleled opportunity to advance novel antibody solutions from concept to commercialization.
- Full-Spectrum Pipeline: High-throughput single B-cell screening, precision sequencing (NTGC), and scalable biomanufacturing (NCTM²) for end-to-end development.
- AI-Driven Discovery: Rapid identification of internalizing antibodies optimized for antibody-drug conjugates and next-generation therapeutics.
Expanded Research Ecosystem at UTA
In addition to IMPRINT, UTA offers a robust network of specialized research centers that enhance the capabilities of the IMPRINT Antibody Discovery Program:
CIHI – Center for Innovation in Health Informatics
Driving advancements in health data science, CIHI supports AI-driven antibody modeling and precision health analytics.
CIRC – Clinical Imaging Research Center
Provides advanced imaging capabilities for translational research, enabling visualization and validation of antibody-target interactions.
NTGC – North Texas Genome Center
A high-throughput sequencing powerhouse, NTGC accelerates genomic insights critical to antibody development and personalized medicine.
BMRC – Bone-Muscle Research Center
Focused on musculoskeletal health, BMRC offers unique opportunities for antibody applications in regenerative medicine and chronic disease.
Together, these centers form a comprehensive innovation ecosystem that supports discovery, development, and deployment of next-generation antibody therapeutics.